Loading...
XHKG
2170
Market cap100mUSD
Jul 28, Last price  
2.89HKD
1D
0.70%
1Q
-9.69%
Name

Suzhou Basecare Medical Co Ltd

Chart & Performance

D1W1MN
XHKG:2170 chart
No data to show
P/E
P/S
2.40
EPS
Div Yield, %
Shrs. gr., 5y
0.51%
Rev. gr., 5y
39.96%
Revenues
299m
+43.82%
32,609,00055,685,00081,109,000107,299,000140,901,000207,976,000299,109,000
Net income
-237m
L+23.66%
-154,877,000-531,336,000-877,052,000-143,651,000-123,163,000-191,685,000-237,029,000
CFO
0k
P
-26,695,000-38,145,000-64,288,000-197,852,000-188,769,000-267,234,0000

Profile

Suzhou Basecare Medical Corporation Limited, an investment holding company, engages in the research, development, manufacture, and provision of genetic testing solutions for assisted reproduction and sale of genetic testing devices and instruments in the People's Republic of China. The company offers genetic test kit products, which include pre-implantation genetic test kits, such as PGT-A to detect aneuploidy; PGT-M to detect single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kits to detect chromosome structural rearrangements, which are common causes of recurrent miscarriage. It also provides prenatal test kit products comprising CNV kits; postnatal test kit products consist of WES kits; and devices and instruments, including liquid nitrogen storage dewar, cryostorage system, automated workstation, sperm quality analyzer, and NGS sequencer. The company also engages in the research, development, manufacture, and sale of medical devices and instruments. In addition, it provides marketing services; and engages in the research and development of software for medical devices and instruments. The company serves hospitals and reproductive clinics. Suzhou Basecare Medical Corporation Limited was incorporated in 2010 and is headquartered in Suzhou, China.
IPO date
Employees
479
Domiciled in
CN
Incorporated in

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
299,109
43.82%
207,976
47.60%
140,901
31.32%
Cost of revenue
574,533
455,492
362,641
Unusual Expense (Income)
NOPBT
(275,424)
(247,516)
(221,740)
NOPBT Margin
Operating Taxes
3,127
(2,970)
6,013
Tax Rate
NOPAT
(278,551)
(244,546)
(227,753)
Net income
(237,029)
23.66%
(191,685)
55.64%
(123,163)
-14.26%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
28,766
15,186
2,146
Long-term debt
307,509
278,516
75,540
Deferred revenue
2,520
380
Other long-term liabilities
33,128
380
Net debt
(377,006)
(672,428)
(1,274,844)
Cash flow
Cash from operating activities
(267,234)
(188,769)
CAPEX
(104,208)
(128,751)
Cash from investing activities
(324,814)
(88,698)
Cash from financing activities
190,551
23,514
FCF
(352,142)
(401,207)
(331,267)
Balance
Cash
687,156
945,712
1,332,146
Long term investments
26,125
20,418
20,384
Excess cash
698,326
955,731
1,345,485
Stockholders' equity
1,141,815
(279,173)
(85,747)
Invested Capital
805,037
1,961,716
1,749,081
ROIC
ROCE
EV
Common stock shares outstanding
273,526
273,526
273,526
Price
2.74
16.60%
2.35
-37.00%
3.73
-43.05%
Market cap
749,461
16.60%
642,786
-37.00%
1,020,252
-41.29%
EV
371,204
(30,712)
(255,862)
EBITDA
(275,424)
(227,949)
(213,353)
EV/EBITDA
0.13
1.20
Interest
2,610
3,109
Interest/NOPBT